Specify a stock or a cryptocurrency in the search bar to get a summary
Eloxx Pharmaceuticals Inc
ELOXEloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts. Address: 480 Arsenal Way, Watertown, MA, United States, 02472
Analytics
WallStreet Target Price
30 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ELOX
Dividend Analytics ELOX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ELOX
Stock Valuation ELOX
Financials ELOX
Results | 2019 | Dynamics |